- Endologix (NASDAQ:ELGX +6%) announced its preliminary unaudited revenue for Q4 and FY 2018 to be ~$34M and $155.8M respectively.
- Total cash, equivalents, and restricted cash as of December 31, 2018 are expected to be ~$24M.
- Reaffirmed Guidance: Revenues of ~$35M and $140M for Q1 2019 and FY 2019 respectively; operating expenses for FY 2019 in the range of $130-140M.
- #JPM19